Chiron Capital Management’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.58M | Sell |
79,338
-4,557
| -5% | -$378K | 5.72% | 2 |
|
|
2025
Q1 | $6.8M | Sell |
83,895
-3,307
| -4% | -$268K | 6.18% | 2 |
|
|
2024
Q4 | $7.85M | Sell |
87,202
-1,703
| -2% | -$153K | 7.41% | 2 |
|
|
2024
Q3 | $8.78M | Sell |
88,905
-2,449
| -3% | -$242K | 7.77% | 2 |
|
|
2024
Q2 | $8.47M | Sell |
91,354
-718
| -0.8% | -$66.6K | 8.09% | 2 |
|
|
2024
Q1 | $8.74M | Sell |
92,072
-48,517
| -35% | -$4.6M | 7.94% | 2 |
|
|
2023
Q4 | $12.6M | Sell |
140,589
-8,117
| -5% | -$725K | 10.92% | 2 |
|
|
2023
Q3 | $10.9M | Buy |
148,706
+10,496
| +8% | +$766K | 9.34% | 2 |
|
|
2023
Q2 | $11.5M | Sell |
138,210
-29,100
| -17% | -$2.42M | 9.11% | 2 |
|
|
2023
Q1 | $12.8M | Buy |
167,310
+17,883
| +12% | +$1.36M | 8.86% | 2 |
|
|
2022
Q4 | $12.4M | Sell |
149,427
-8,871
| -6% | -$736K | 8.63% | 2 |
|
|
2022
Q3 | $12.6M | Sell |
158,298
-8,528
| -5% | -$676K | 8.44% | 2 |
|
|
2022
Q2 | $12.4M | Buy |
166,826
+8,619
| +5% | +$640K | 7.82% | 2 |
|
|
2022
Q1 | $14.2M | Buy |
158,207
+112,928
| +249% | +$10.2M | 8.96% | 2 |
|
|
2021
Q4 | $5.07M | Buy |
45,279
+5,753
| +15% | +$644K | 3.66% | 3 |
|
|
2021
Q3 | $4.97M | Buy |
39,526
+31,015
| +364% | +$3.9M | 3.62% | 4 |
|
|
2021
Q2 | $1.15M | Buy |
8,511
+5,692
| +202% | +$770K | 0.96% | 24 |
|
|
2021
Q1 | $382K | Buy |
2,819
+507
| +22% | +$68.7K | 0.32% | 52 |
|
|
2020
Q4 | $325K | Sell |
2,312
-1,680
| -42% | -$236K | 0.27% | 60 |
|
|
2020
Q3 | $445K | Buy |
+3,992
| New | +$445K | 0.36% | 42 |
|